2025 Q4 -tulosraportti
27 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 420 | - | - | ||
| 80 | - | - | ||
| 25 500 | - | - | ||
| 5 000 | - | - | ||
| 3 849 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 104 205 | 104 205 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 104 205 | 104 205 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·9 t sittenThere has been a seminar which you can read about by clicking on the link. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/- ·2 päivää sittenOnly for those interested, everyone else ignore this post. I was curious about how it can be that Bioporto now uses the 510K application form for FDA approval for adults, and not de novo. What does it cost to get an approval from the FDA? The following is what I have found out. Bioporto uses 510K, and not de novo, because de novo is for products that are new to the market, and the test for adults is not. This time Bioporto must show that the test for adults works, and not as with the children's test, that they must have evidence that the test works. Since Bioporto is the originator of the children's test, which is used as a benchmark at the FDA, Bioporto must show that the test for adults is just as good as for children. Therefore, Bioporto's management states that the test for adults will be approved by 2027 at the latest, because the test for adults is compared with the test for children, which they themselves invented. The de novo application can only be obtained once, so this time it will cost Bioporto something to get an approval from the FDA. Because Bioporto is a smaller company, with revenue less than 100.000 $ per year, Bioporto gets a discount. Bioporto only has to pay approx. 41.000 kr, instead of the full amount approx. 165.100 kr. This is the explanation I could find for how it can be that Bioporto has announced that they expect the adult test to be FDA approved by 2027 at the latest. After they have sold the antibodies, they have also announced that they do not expect any issuance, which they can, because the process for approval for adults will be much cheaper than when the test for children had to be approved.·7 t sittenThe crucial thing must be that the test is approved, and in that context, I think it must be of less importance whether it is via de Novo or 510K. I don't know if that's the right word to use, but let it pass, I think the FDA can probably use the children's version as a benchmark in connection with the approval. The most crucial thing, however, must be the future/expected sales, and in that respect, it should probably be just as or actually more relevant again to use the children's version as a benchmark for the adult version, and that doesn't make me particularly optimistic? If hospitals can't see a point in using ngal for treating children, why should they see a point in using ngal for adults?
·15.4.Following my post on 8. March, management's shareholdings in BioPorto are a strong optimistic signal, as stated in Carnegie's report page 48. Among the company's ten largest shareholders are CEO, CLO, former CEO, chairman and vice charirman. The ten largest shareholders hold approx. 33%. Since Martin Bundgaard first flagged his 5% on Monday, they are not included in Carnegie's overview. From my post on 8. March: 2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism. The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl joined on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his employment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.- ·15.4.
·13.4.Until the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
27 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sittenThere has been a seminar which you can read about by clicking on the link. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/
- ·2 päivää sittenOnly for those interested, everyone else ignore this post. I was curious about how it can be that Bioporto now uses the 510K application form for FDA approval for adults, and not de novo. What does it cost to get an approval from the FDA? The following is what I have found out. Bioporto uses 510K, and not de novo, because de novo is for products that are new to the market, and the test for adults is not. This time Bioporto must show that the test for adults works, and not as with the children's test, that they must have evidence that the test works. Since Bioporto is the originator of the children's test, which is used as a benchmark at the FDA, Bioporto must show that the test for adults is just as good as for children. Therefore, Bioporto's management states that the test for adults will be approved by 2027 at the latest, because the test for adults is compared with the test for children, which they themselves invented. The de novo application can only be obtained once, so this time it will cost Bioporto something to get an approval from the FDA. Because Bioporto is a smaller company, with revenue less than 100.000 $ per year, Bioporto gets a discount. Bioporto only has to pay approx. 41.000 kr, instead of the full amount approx. 165.100 kr. This is the explanation I could find for how it can be that Bioporto has announced that they expect the adult test to be FDA approved by 2027 at the latest. After they have sold the antibodies, they have also announced that they do not expect any issuance, which they can, because the process for approval for adults will be much cheaper than when the test for children had to be approved.·7 t sittenThe crucial thing must be that the test is approved, and in that context, I think it must be of less importance whether it is via de Novo or 510K. I don't know if that's the right word to use, but let it pass, I think the FDA can probably use the children's version as a benchmark in connection with the approval. The most crucial thing, however, must be the future/expected sales, and in that respect, it should probably be just as or actually more relevant again to use the children's version as a benchmark for the adult version, and that doesn't make me particularly optimistic? If hospitals can't see a point in using ngal for treating children, why should they see a point in using ngal for adults?
- ·15.4.Following my post on 8. March, management's shareholdings in BioPorto are a strong optimistic signal, as stated in Carnegie's report page 48. Among the company's ten largest shareholders are CEO, CLO, former CEO, chairman and vice charirman. The ten largest shareholders hold approx. 33%. Since Martin Bundgaard first flagged his 5% on Monday, they are not included in Carnegie's overview. From my post on 8. March: 2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism. The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl joined on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his employment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.
- ·15.4.
- ·13.4.Until the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 420 | - | - | ||
| 80 | - | - | ||
| 25 500 | - | - | ||
| 5 000 | - | - | ||
| 3 849 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 104 205 | 104 205 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 104 205 | 104 205 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
27 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·9 t sittenThere has been a seminar which you can read about by clicking on the link. https://www.linkedin.com/feed/update/urn:li:activity:7451975532352704514/
- ·2 päivää sittenOnly for those interested, everyone else ignore this post. I was curious about how it can be that Bioporto now uses the 510K application form for FDA approval for adults, and not de novo. What does it cost to get an approval from the FDA? The following is what I have found out. Bioporto uses 510K, and not de novo, because de novo is for products that are new to the market, and the test for adults is not. This time Bioporto must show that the test for adults works, and not as with the children's test, that they must have evidence that the test works. Since Bioporto is the originator of the children's test, which is used as a benchmark at the FDA, Bioporto must show that the test for adults is just as good as for children. Therefore, Bioporto's management states that the test for adults will be approved by 2027 at the latest, because the test for adults is compared with the test for children, which they themselves invented. The de novo application can only be obtained once, so this time it will cost Bioporto something to get an approval from the FDA. Because Bioporto is a smaller company, with revenue less than 100.000 $ per year, Bioporto gets a discount. Bioporto only has to pay approx. 41.000 kr, instead of the full amount approx. 165.100 kr. This is the explanation I could find for how it can be that Bioporto has announced that they expect the adult test to be FDA approved by 2027 at the latest. After they have sold the antibodies, they have also announced that they do not expect any issuance, which they can, because the process for approval for adults will be much cheaper than when the test for children had to be approved.·7 t sittenThe crucial thing must be that the test is approved, and in that context, I think it must be of less importance whether it is via de Novo or 510K. I don't know if that's the right word to use, but let it pass, I think the FDA can probably use the children's version as a benchmark in connection with the approval. The most crucial thing, however, must be the future/expected sales, and in that respect, it should probably be just as or actually more relevant again to use the children's version as a benchmark for the adult version, and that doesn't make me particularly optimistic? If hospitals can't see a point in using ngal for treating children, why should they see a point in using ngal for adults?
- ·15.4.Following my post on 8. March, management's shareholdings in BioPorto are a strong optimistic signal, as stated in Carnegie's report page 48. Among the company's ten largest shareholders are CEO, CLO, former CEO, chairman and vice charirman. The ten largest shareholders hold approx. 33%. Since Martin Bundgaard first flagged his 5% on Monday, they are not included in Carnegie's overview. From my post on 8. March: 2026 could be a very good year for BioPorto: The sentiment for biotech on Wall Street has turned significantly at the beginning of 2026, and the IPO market (initial public offerings) shows clear signs of life after several years of dormancy. After a very quiet 2024 and a historically weak 2025, investors have returned with renewed optimism. The Chairman, Jens Due Olsen, has invested approx. 6 million kr. of his own funds in 2025 (at prices 1.34 and 1.07 in the two emissions). Remarkable for a company of BioPorto's size. * Signal: Chairmen in biotech companies rarely make million-dollar investments shortly before crucial clinical data, unless they have a very strong belief in the company's fundamental value and the preliminary observations from the studies. * Risk/Reward: He bought in at a time when the stock is close to its historical low, which suggests that he sees a significant asymmetric gain opportunity when the adult data is expected to land later in 2026 Carsten Buhl joined on 1. September 2025, as the new CEO, and already in November chose to invest approx. 500,000 kr. in the emission. * Insight: As CEO, he has direct responsibility for the execution of the clinical study for adults. His willingness to invest his own money so quickly after his employment is interpreted as him "liking what he sees" in the internal processes and in the dialogue with the American clinics.
- ·15.4.
- ·13.4.Until the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 9 420 | - | - | ||
| 80 | - | - | ||
| 25 500 | - | - | ||
| 5 000 | - | - | ||
| 3 849 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 104 205 | 104 205 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 104 205 | 104 205 | 0 | 0 |